Tags

Type your tag names separated by a space and hit enter

Yeast as a drug discovery platform in Huntington's and Parkinson's diseases.
Biotechnol J. 2006 Mar; 1(3):258-69.BJ

Abstract

The high degree of conservation of cellular and molecular processes between the budding yeast Saccharomyces cerevisiae and higher eukaryotes have made it a valuable system for numerous studies of the basic mechanisms behind devastating illnesses such as cancer, infectious disease, and neurodegenerative disorders. Several studies in yeast have already contributed to our basic understanding of cellular dysfunction in both Huntington's and Parkinson's disease. Functional genomics approaches currently being undertaken in yeast may lead to novel insights into the genes and pathways that modulate neuronal cell dysfunction and death in these diseases. In addition, the budding yeast constitutes a valuable system for identification of new drug targets, both via target-based and non-target-based drug screening. Importantly, yeast can be used as a cellular platform to analyze the cellular effects of candidate compounds, which is critical for the development of effective therapeutics. While the molecular mechanisms that underlie neurodegeneration will ultimately have to be tested in neuronal and animal models, there are several distinct advantages to using simple model organisms to elucidate fundamental aspects of protein aggregation, amyloid toxicity, and cellular dysfunction. Here, we review recent studies that have shown that amyloid formation by disease-causing proteins and many of the resulting cellular deficits can be faithfully recapitulated in yeast. In addition, we discuss new yeast-based techniques for screening candidate therapeutic compounds for Huntington's and Parkinson's diseases.

Authors+Show Affiliations

Whitehead Institute for Biomedical Research, MIT, Cambridge, MA, USA. touteiro@partners.orgNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16897706

Citation

Outeiro, Tiago Fleming, and Flaviano Giorgini. "Yeast as a Drug Discovery Platform in Huntington's and Parkinson's Diseases." Biotechnology Journal, vol. 1, no. 3, 2006, pp. 258-69.
Outeiro TF, Giorgini F. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnol J. 2006;1(3):258-69.
Outeiro, T. F., & Giorgini, F. (2006). Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. Biotechnology Journal, 1(3), 258-69.
Outeiro TF, Giorgini F. Yeast as a Drug Discovery Platform in Huntington's and Parkinson's Diseases. Biotechnol J. 2006;1(3):258-69. PubMed PMID: 16897706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. AU - Outeiro,Tiago Fleming, AU - Giorgini,Flaviano, PY - 2006/8/10/pubmed PY - 2006/9/27/medline PY - 2006/8/10/entrez SP - 258 EP - 69 JF - Biotechnology journal JO - Biotechnol J VL - 1 IS - 3 N2 - The high degree of conservation of cellular and molecular processes between the budding yeast Saccharomyces cerevisiae and higher eukaryotes have made it a valuable system for numerous studies of the basic mechanisms behind devastating illnesses such as cancer, infectious disease, and neurodegenerative disorders. Several studies in yeast have already contributed to our basic understanding of cellular dysfunction in both Huntington's and Parkinson's disease. Functional genomics approaches currently being undertaken in yeast may lead to novel insights into the genes and pathways that modulate neuronal cell dysfunction and death in these diseases. In addition, the budding yeast constitutes a valuable system for identification of new drug targets, both via target-based and non-target-based drug screening. Importantly, yeast can be used as a cellular platform to analyze the cellular effects of candidate compounds, which is critical for the development of effective therapeutics. While the molecular mechanisms that underlie neurodegeneration will ultimately have to be tested in neuronal and animal models, there are several distinct advantages to using simple model organisms to elucidate fundamental aspects of protein aggregation, amyloid toxicity, and cellular dysfunction. Here, we review recent studies that have shown that amyloid formation by disease-causing proteins and many of the resulting cellular deficits can be faithfully recapitulated in yeast. In addition, we discuss new yeast-based techniques for screening candidate therapeutic compounds for Huntington's and Parkinson's diseases. SN - 1860-6768 UR - https://www.unboundmedicine.com/medline/citation/16897706/Yeast_as_a_drug_discovery_platform_in_Huntington's_and_Parkinson's_diseases_ L2 - https://doi.org/10.1002/biot.200500043 DB - PRIME DP - Unbound Medicine ER -